Brazil Threatens To Break Patent On Abbott's Kaletra

By Marius Meland

Law360, New York (June 26, 2005, 12:00 AM ET) -- Brazil has vowed to break the patent on U.S. drug maker Abbott Laboratories' HIV drug Kaletra in an effort to cut treatment costs.

Brazilian Health Minister Humberto Costa told local media his government would break the patent as a matter of “public interest.”

He said Abbott would be given 10 days in which to respond and seek a negotiated agreement.

“The Brazilian government will adopt a compulsory licence for the treatment if the manufacturer (Abbott) does not accept the presented terms to guarantee the sustainability of...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles